Rinascera launches with initial funding to tackle rare skin diseases
What's the deal? Rinascera Therapeutics, a clinical-stage biotech developing treatments for rare genetic skin diseases, has launched with initial financing led by Double Point VenturesDealroom has a profile for this one. Try Dealroom →. Olive Tree CapitalDealroom has a profile for this one. Try Dealroom →, Civilization VenturesDealroom has a profile for this one. Try Dealroom →, and Toba CapitalDealroom has a profile for this one. Try Dealroom → joined the round.
What's the endgame? The company, incubated by Olive Tree Capital, wants to build a commercially focused rare disease biotech targeting the biological causes of inherited skin disorders rather than managing symptoms. Its name draws on the Italian "rinascere," meaning "to be reborn."
Rinascera has two clinical-stage programs, both with proof-of-concept results and headed into later-stage trials. RIN-001 is a topical kinase inhibitor for Gorlin Syndrome and recurrent basal cell carcinomas, designed to treat early tumours before surgery is needed. RIN-002, acquired from BridgeBio, is an intravenous collagen VII replacement therapy for Dystrophic Epidermolysis Bullosa, aimed at repairing fragile skin throughout the body.
Why it matters? Standard care for these conditions often relies on repeated surgeries and wound-by-wound management. "Patients living with Gorlin Syndrome and DEB need treatments that offer meaningful improvements rather than temporary relief," said co-founder and chief executive officer Nichola Eliovits.
Who's behind it? The founding team pairs Eliovits with chief operating officer Max Dawson and executive medical advisor Karl Beutner. Dan Yadegar, managing partner at Double Point Ventures, joins the board and said the company combines "experienced leadership with promising clinical-stage programs."
The signal: Backing a startup with two de-risked, proof-of-concept assets — one in-licensed from BridgeBio — reflects investor appetite for rare disease bets with clearly defined biology and high unmet need, where success can reshape a small but underserved treatment market.
Read more: PharmaNow
